Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05790603

Effect of Patent Hemostatic Device (PHD) With Quantitative Pressure on Radial Artery Hemostasis After CAG/PCI

The objective of this clinical trial is to compare the hemostatic effect of 2 hemostatic devices with or without quantitative pressure on radial arteries after coronary angiography (CAG) or percutaneous coronary intervention (PCI). The main questions aims to answer:

* What is the hemostatic effect of the patent hemostatic device with quantitative pressure after percutaneous coronary intervention? * What are the precise hemostatic pressure and hemostatic time of the radial artery after CAG/PCI? Participants will be randomly assigned to the intervention group (IG) and control group (CG). The IG will use patent hemostatic device with quantitative pressure (PHDQP-Band, China) while the CG will use the conventional radial artery hemostatic device (TR-Band, Japan) without pressure monitoring.

The primary outcomes is incidence of 24h radial artery occlusion (24h RAO). Secondary outcomes include time to hemostasis, bleeding, hematoma, 30d radial artery occlusion (30d RAO), pain, hand swelling, numberness, pseudoaneurysm, and radial artery stenosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Xuanwu Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

The objective of this clinical trial is to compare the hemostatic effect of 2 hemostatic devices with or without quantitative pressure on radial arteries after percutaneous coronary intervention. The main questions aims to answer:

  • What is the hemostatic effect of the patent hemostatic device after percutaneous coronary intervention?
  • What are the precise hemostasis pressure and hemostasis time of the radial artery after percutaneous coronary intervention?

Participants will be randomly assigned to the intervention group (IG) and control group (CG).

For the participants assigned to the IG, the radial systolic pressure will be measured after TRA procedure. The PHD-Band with quantitative pressure ( WEGO Medical Products Group CO. LTD, China) will be placed at the entry site of the sheath. Connecting the hemostatic devices to the electric pneumatic machine with a connecting cable. After removing the radial sheath, the puncture site will be compressed by operator's hand. The PHD-Band with quantitative pressure will be inflated with specific pressure radial systolic pressure plus 10mmHg) and the hand will slowly release the pressure. If bleeding occurs, the PHD-Band will be deflated with 5-10mmHg automatically by parameter setting with the electric pneumatic machine until the bleeding stops. The PHD-Band will be deflated with20 mmHg, 40 mmHg of decreased pressure following 1h and 2h after the procedure. After 3 hours, the hemostatic pressure will be released to 45mmHg and the PHD-Band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated according to the previous pressure for another an hour until bleeding stops.

For the participants assigned to the CG, the TR-Band (Terumo Medical Corporation, Japan) will be placed at the entry site of the sheath after TRA procedure and inflated with 10 mL of air and the radial sheath will be removed with hand compression. Another 5 mL of air will be inflated and the operator's hand will slowly release the pressure. The TR band will be inflated until bleeding stopped with the maximum air volume no more than 18ml. The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be deflated with 4 mL of air first and then all volume of the rest air if no bleeding occurs and then the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with 1 mL of air until bleeding stops .

For all enrolled participants, the investigators will record the complications such as bleeding, subcutaneous hematoma, pain, hand swelling, numbness, pseudoaneurysm after the operation. Radial artery occlusion, subcutaneous hematoma, pseudoaneurysm, and radial artery stenosis were confirmed by arterial ultrasound within 24 hours and 30 days after surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients undergoing coronary angiography or percutaneous coronary intervention via the radial artery; Positive Allen's test result; Willing to sign informed consent.

Exclusion criteria

Radial artery malformation; Chronic kidney disease with eGFR<30ml/min.1.73m2; Cirrhosis of the liver; Coagulation disfunction; Patients treated with IIb / IIIa receptor antagonist.

Treatment and study plan

Intervention group with PHD-Band

Device

The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.

Other names: Brand name: WEGO Medical Products Group CO. LTD, China

Control group with TR-Band

Device

TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .

Other names: Brand name: Terumo Medical Corporation, Japan

Primary outcomes

  1. Incidence early radial artery occlusion

    Time frame: Within 24 hours after CAG/PCI

    RAO occurs within 24 hours after CAG/PCI

Secondary outcomes

  1. Compression time

    Time frame: through hemostasis completion,estimated to be an average of 3~6hours

    The interval from the time of sheath removal to the time of hemostasis removal

  2. Incidence of access site bleeding

    Time frame: Within 24 hours after CAG/PCI

    Access site bleeding within 24 hours after CAG/PCI

  3. Incidence of hematoma

    Time frame: through hemostasis completion,estimated to be an average of 4~6hours

    The incidence of subcutaneous hematoma in the distal skin of the compression site 24 h after the removal of the compression device

  4. Incidence of 30d radial artery occlusion

    Time frame: Within 30 days after CAG/PCI

    RAO occurs within 30 days after CAG/PCI

  5. The degree of pain

    Time frame: baseline; 24 hours after PCI

    Pain level is classified as painless: 0; mild pain: 1~3; moderate pain: 4~6; severe pain: 7~10.

  6. numbness

    Time frame: baseline; 24 hours after PCI

    Numbness level is classified as no numbness with 0, mild numbness: 1~2; moderate numbness: 3; severe numbness:4~5

  7. Hand swelling

    Time frame: baseline; 24 hours after PCI

    The circumference diameter of both hands was measured using a tape gauge contrast.

  8. pseudoaneurysm

    Time frame: Within 24 hours after PCI

    It refers to the lumen of the same as the artery formed by the blood through the perivascular tissue after arterial puncture.

Study contacts

Contact information is provided by the study sponsor or research team.

Zhenhui Tao

CONTACT

[email protected]

+8613811839842

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Collaborators

  • Xuanwu Hospital, Beijing

Registry information

Official study title

Effect of Patent Hemostatic Device (PHD) With Quantitative Pressure on Radial Artery Hemostasis After CAG/PCI:a Randomized Controlled Trial

Acronym: PCI

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 30, 2023
Registry last updated
Jul 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.